Kyverna Therapeutics Announces Positive Interim Phase 2 Data for KYV-101 in Generalized Myasthenia Gravis

Kyverna Therapeutics, Inc. reported positive interim data from the Phase 2 portion of its KYSA-6 Phase 2/3 trial for KYV-101 in generalized myasthenia gravis (gMG). The data showed that 100% of patients achieved clinically meaningful responses in the co-primary endpoints, MG-ADL and QMG, with mean reductions of -8.0 and -7.7 points at 24 weeks, respectively. KYV-101 was well-tolerated with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed. The results reinforce the potential of KYV-101 to deliver durable, drug-free, disease-free remission with a single dose. The company will host a conference call to review the results on October 29, 2025.